Atara Biotherapeutics: Nguyen reports 113-share sale plan
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atara Biotherapeutics, Inc. director and officer AnhCo Nguyen reported a proposed sale of 113 common shares, with an aggregate market value of $734.5 and an approximate sale date of November 17, 2026. The shares are to be sold automatically to satisfy tax withholding obligations tied to vesting previously granted restricted stock units, under a sale-to-cover provision in the award agreement. Nguyen acquired 13,887 shares on November 15, 2026, through settlement of vested RSUs issued under an S-8 Registration Plan as equity compensation for services rendered.
Key Figures
Key Terms
restricted stock units financial
sale-to-cover provision financial
S-8 Registration Plan regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.